The Overlooked Immune State in Candidemia: A Risk Factor for Mortality

• Main Authors: Christian Ortega-Loubon, Beatriz Cano-Hernández, Rodrigo Poves-Alvarez, María Fe Muñoz-Moreno, Patricia Román-García, Sara Balbás-Alvarez, Olga de la Varga-Martínez, Esther Gómez-Sánchez, Estefanía Gómez-Pesquera, Mario Lorenzo-López, Eduardo Tamayo, María Heredia-Rodríguez
• Format: Article
• Language: English
• Published: MDPI AG 2019-09-01
• Series: Journal of Clinical Medicine
• Subjects: lymphopenia; lymphocyte count; candidemia; mortality; prognosis; survival; immunosuppression
• Online Access: https://www.mdpi.com/2077-0383/8/10/1512

Lymphopenia has been related to increased mortality in septic patients. Nonetheless, the impact of lymphocyte count on candidemia mortality and prognosis has not been addressed. We conducted a retrospective study, including all admitted patients with candidemia from 2007 to 2016. We examined lymphocyte counts during the first 5 days following the diagnosis of candidemia. Multivariable logistic regression analysis was performed to determine the relationship between lymphocyte count and mortality. Classification and Regression Tree analysis was used to identify the best cut-off of lymphocyte count for mortality associated with candidemia. From 296 cases of candidemia, 115 died, (39.8% 30-day mortality). Low lymphocyte count was related to mortality and poor outcome (<i>p</i> &lt; 0.001). Lymphocyte counts &lt;0.703 &#215; 10⁹ cells/L at diagnosis (area under the curve (AUC)-ROC, 0.783 &#177; 0.042; 95% confidence interval (CI), 0.700&#8722;0.867, <i>p</i> &lt; 0.001), and lymphocyte count &lt;1.272 &#215; 10⁹ cells/L five days later (AUC-ROC, 0.791 &#177; 0.038; 95%CI, 0.716&#8722;0.866, <i>p</i> &lt; 0.001) increased the odds of mortality five-fold (odds ratio (OR), 5.01; 95%CI, 2.39&#8722;10.93) at time of diagnosis, and three-fold (OR, 3.27; 95%CI, 1.24&#8722;8.62) by day 5, respectively. Low lymphocyte count is an independent predictor of mortality in patients with candidemia and might serve as a biomarker for predicting candidemia-associated mortality and poor outcome.